Intestinal Research最新文献

{"title":"Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn's disease in tuberculosis endemic areas.","authors":"Karan Sachdeva,&nbsp;Peeyush Kumar,&nbsp;Bhaskar Kante,&nbsp;Sudheer K Vuyyuru,&nbsp;Srikant Mohta,&nbsp;Mukesh K Ranjan,&nbsp;Mukesh K Singh,&nbsp;Mahak Verma,&nbsp;Govind Makharia,&nbsp;Saurabh Kedia,&nbsp;Vineet Ahuja","doi":"10.5217/ir.2022.00010","DOIUrl":"https://doi.org/10.5217/ir.2022.00010","url":null,"abstract":"<p><strong>Background/aims: </strong>Intestinal tuberculosis (ITB) and Crohn's disease (CD) frequently present with a diagnostic dilemma because of similar presentation. Interferon-gamma release assay (IGRA) has been used in differentiating ITB from CD, but with sparse reports on its diagnostic accuracy in tuberculosis endemic regions and this study evaluated the same.</p><p><strong>Methods: </strong>Patients with definitive diagnosis of ITB (n=59) or CD (n=49) who underwent IGRA testing (n=307) were retrospectively included at All India Institute of Medical Sciences, New Delhi (July 2014 to September 2021). CD or ITB was diagnosed as per standard criteria. IGRA was considered positive at >0.35 IU/mL. Relevant data was collected and IGRA results were compared between ITB and CD to determine its accuracy.</p><p><strong>Results: </strong>Among 59 ITB patients (mean age, 32.6±13.1 years; median disease duration, 1 year; male, 59.3%), 24 were positive and 35 tested negative for IGRA. Among 49 CD patients (mean age, 37.8±14.0; median disease duration, 4 years; male, 61.2%), 12 were positive and 37 tested negative for IGRA. Hence, for diagnosing ITB, IGRA showed a sensitivity, specificity, positive and negative predictive values of 40.68%, 75.51%, 66.67%, and 51.39%, respectively. The area under the curve of IGRA for ITB diagnosis was 0.66 (95% confidence interval, 0.55-0.75). In a subset (n=64), tuberculin skin test (TST) showed sensitivity, specificity, positive and negative predictive values of 64.7%, 73.3%, 73.3%, and 64.71%, respectively. IGRA and TST were concordant in 38 (59.4%) patients with κ=0.17.</p><p><strong>Conclusions: </strong>In a tuberculosis endemic region, IGRA had poor diagnostic accuracy for differentiating ITB from CD, suggesting a limited value of IGRA in this setting.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/0f/ir-2022-00010.PMC10169514.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9447707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study.","authors":"Eun Hye Oh,&nbsp;Ye-Jee Kim,&nbsp;Minju Kim,&nbsp;Seung Ha Park,&nbsp;Tae Oh Kim,&nbsp;Sang Hyoung Park","doi":"10.5217/ir.2022.00092","DOIUrl":"https://doi.org/10.5217/ir.2022.00092","url":null,"abstract":"<p><strong>Background/aims: </strong>We conducted a nationwide population-based study to investigate incidence rates of colorectal and biliary cancers according to accompanying primary sclerosing cholangitis in Korean ulcerative colitis patients.</p><p><strong>Methods: </strong>We used the Health Insurance Review and Assessment claim database from January 2007 to April 2020. Standardized incidence ratios of colorectal and biliary cancers in ulcerative colitis patients were calculated.</p><p><strong>Results: </strong>Among 35,189 newly diagnosed ulcerative colitis patients, 1,224 patients were diagnosed with primary sclerosing cholangitis. During the study period, 122 and 52 patients were diagnosed with colorectal and biliary cancers, respectively. Incidences of colorectal cancer were not higher in ulcerative colitis patients than those in the general population (standardized incidence ratios, 0.83; 95% confidence interval, 0.69-0.99), regardless of accompanied primary sclerosing cholangitis (standardized incidence ratio, 0.73; 95% confidence interval, 0.24-1.71). While incidences of biliary cancer were not higher in ulcerative colitis patients than those in the general population (standardized incidence ratio, 1.14; 95% confidence interval, 0.80-1.58), these were much higher with accompanied primary sclerosing cholangitis (standardized incidence ratio, 10.07; 95% confidence interval, 5.75-16.36). Cumulative incidences of colorectal and biliary cancers increased in patients who were diagnosed with ulcerative colitis at an older age.</p><p><strong>Conclusions: </strong>In Korean ulcerative colitis patients, colorectal cancer incidences were not higher than those in the general population regardless of accompanied primary sclerosing cholangitis. However, biliary cancer incidences were much higher in ulcerative colitis patients with primary sclerosing cholangitis than in those without, or in the general population.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/e9/ir-2022-00092.PMC10169518.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9450393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical spectrum of elderly-onset inflammatory bowel disease in India.","authors":"Yogesh Kumar Gupta,&nbsp;Arshdeep Singh,&nbsp;Vikram Narang,&nbsp;Vandana Midha,&nbsp;Ramit Mahajan,&nbsp;Varun Mehta,&nbsp;Dharmatma Singh,&nbsp;Namita Bansal,&nbsp;Madeline Vithya Barnaba Durairaj,&nbsp;Amit Kumar Dutta,&nbsp;Ajit Sood","doi":"10.5217/ir.2021.00177","DOIUrl":"https://doi.org/10.5217/ir.2021.00177","url":null,"abstract":"<p><strong>Background/aims: </strong>Inflammatory bowel disease (IBD) is increasingly being recognized in elderly patients. Data on clinical spectrum of elderly-onset IBD patients is lacking from India.</p><p><strong>Methods: </strong>A cross-sectional retrospective analysis of a prospectively maintained database of patients diagnosed with IBD was conducted at 2 centers in India. The clinical spectrum of elderly-onset IBD including demographic profile (age and sex), clinical presentation, disease characteristics (disease behavior and severity, extent of disease), and treatment were recorded and compared with adult-onset IBD.</p><p><strong>Results: </strong>During the study period, 3,922 (3,172 ulcerative colitis [UC] and 750 Crohn's disease [CD]) patients with IBD were recorded in the database. A total of 186 patients (4.74%; 116 males [62.36%]) had elderly-onset IBD (69.35% UC and 30.64% CD). Diarrhea, blood in stools, nocturnal frequency and pain abdomen were the commonest presentations for UC, whereas pain abdomen, weight loss and diarrhea were the most frequent symptoms in CD. For both elderly onset UC and CD, majority of the patients had moderately severe disease. Left-sided colitis was the commonest disease location in UC. Isolated ileal disease and inflammatory behavior were the most common disease location and behavior, respectively in CD. 5-Aminosalicylates were the commonest prescribed drug for both elderly onset UC and CD. Thiopurines and biologics were used infrequently. Prevalence of colorectal cancer was higher in elderly onset IBD.</p><p><strong>Conclusions: </strong>Elderly onset IBD is not uncommon in India. Both the elderly onset UC and CD were milder, with no significant differences in disease characteristics (disease extent, location and behavior) when compared to adult-onset IBD. Colorectal cancer was more common in elderly onset IBD.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/76/ir-2021-00177.PMC10169519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease.","authors":"Yu Kyung Jun,&nbsp;Hyuk Yoon,&nbsp;Seong-Joon Koh,&nbsp;A Hyeon Kim,&nbsp;Kwang Woo Kim,&nbsp;Jun Won Park,&nbsp;Hyun Jung Lee,&nbsp;Hyoun Woo Kang,&nbsp;Jong Pil Im,&nbsp;Young Soo Park,&nbsp;Joo Sung Kim","doi":"10.5217/ir.2022.00057","DOIUrl":"https://doi.org/10.5217/ir.2022.00057","url":null,"abstract":"<p><strong>Background/aims: </strong>Patients with inflammatory bowel disease (IBD) are diagnosed with ankylosing spondylitis (AS) often. However, the disease course of patients with both IBD and AS is not well understood. This study aims to evaluate the effect of concomitant AS on IBD outcomes.</p><p><strong>Methods: </strong>Among the 4,722 patients with IBD who were treated in 3 academic hospitals from 2004 to 2021, 55 were also diagnosed with AS (IBD-AS group). Based on patients' electronic medical records, the outcomes of IBD in IBD-AS group and IBD group without AS (IBD-only group) were appraised.</p><p><strong>Results: </strong>The proportion of patients treated with biologics or small molecule therapies was significantly higher in IBD-AS group than the proportion in IBD-only group (27.3% vs. 12.7%, P= 0.036). Patients with both ulcerative colitis and AS had a significantly higher risk of biologics or small molecule therapies than patients with only ulcerative colitis (P< 0.001). For univariable logistic regression, biologics or small molecule therapies were associated with concomitant AS (odds ratio, 4.099; 95% confidence interval, 1.863-9.021; P< 0.001) and Crohn's disease (odds ratio, 3.552; 95% confidence interval, 1.590-7.934; P= 0.002).</p><p><strong>Conclusions: </strong>Concomitant AS is associated with the high possibility of biologics or small molecule therapies for IBD. IBD patients who also had AS may need more careful examination and active treatment to alleviate the severity of IBD.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/43/ir-2022-00057.PMC10169522.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008-2017: a multicenter retrospective study in China.","authors":"Zerong Cai,&nbsp;Xiaosheng He,&nbsp;Jianfeng Gong,&nbsp;Peng Du,&nbsp;Wenjian Meng,&nbsp;Wei Zhou,&nbsp;Jinbo Jiang,&nbsp;Bin Wu,&nbsp;Weitang Yuan,&nbsp;Qi Xue,&nbsp;Lianwen Yuan,&nbsp;Jinhai Wang,&nbsp;Jiandong Tai,&nbsp;Jie Liang,&nbsp;Weiming Zhu,&nbsp;Ping Lan,&nbsp;Xiaojian Wu","doi":"10.5217/ir.2022.00012","DOIUrl":"https://doi.org/10.5217/ir.2022.00012","url":null,"abstract":"<p><strong>Background/aims: </strong>The aim of this study was to analyze the chronological changes in postoperative complications in surgical ulcerative colitis patients over the past decade in China and to investigate the potential parameters that contributed to the changes.</p><p><strong>Methods: </strong>Ulcerative colitis patients who underwent surgery during 2008-2017 were retrospectively enrolled from 13 hospitals in China. Postoperative complications were compared among different operation years. Risk factors for complications were identified by logistic regression analysis.</p><p><strong>Results: </strong>A total of 446 surgical ulcerative colitis patients were analyzed. Fewer short-term complications (24.8% vs. 41.0%, P=0.001) and more laparoscopic surgeries (66.4% vs. 25.0%, P<0.001) were found among patients who received surgery during 2014-2017 than 2008-2013. Logistic regression suggested that independent protective factors against short-term complications were a higher preoperative body mass index (odds ratio [OR], 0.870; 95% confidence interval [CI], 0.785-0.964; P=0.008), laparoscopic surgery (OR, 0.391; 95% CI, 0.217-0.705; P=0.002) and elective surgery (OR, 0.213; 95% CI, 0.067-0.675; P=0.009). The chronological decrease in short-term complications was associated with an increase in laparoscopic surgery.</p><p><strong>Conclusions: </strong>Our data revealed a downward trend of short-term postoperative complications among surgical ulcerative colitis patients in China during the past decade, which may be due to the promotion of minimally invasive techniques among Chinese surgeons.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/8a/ir-2022-00012.PMC10169517.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9450394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviewing not Homer's Iliad, but \"Kai Bao Ben Cao\": indigo dye-the past, present, and future.","authors":"Yusuke Yoshimatsu,&nbsp;Tomohisa Sujino,&nbsp;Takanori Kanai","doi":"10.5217/ir.2022.00018","DOIUrl":"https://doi.org/10.5217/ir.2022.00018","url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 174 UC is a chronic intestinal disease, which has increased worldwide over the last few decades, especially in Asia. Western drugs, such as anti-tumor necrosis factor α and anti-IL-12/23 p40 antibody that provide systemic immunity, are currently used for UC. However, the old Chinese literature “Kai Bao Ben Cao” reported that an indigo compound was used for patients who expressed chronic blood stools around 900 AD. Because we believed in the literature of the past like Schliemann, and Suzuki et al. reported the retrospective study about the efficacy of indigo naturalis (IN), which mainly contains AhR ligands, on patients with UC in Japan, we conducted prospective clinical trial of IN for them, followed by a randomized controlled trial (INDIGO study). As a result, we demonstrated that 8 weeks of IN is safe and effective in patients with UC, even if in treatment refractory patients. Recent Western technologies revealed that AhR ligands lead to innovative treatments that promote the regeneration of mucosal epithelial cells. Of note, IN causes adverse effects, such as headaches, gastrointestinal symptoms, mild liver dysfunction, nonspecific enteritis, bowel intussusception, and pulmonary arterial hypertension. As a consequence, inspired by the anticolitic effect of the AhR ligand, both clinical and basic research studies on the efficacy and safety of IN are being conducted. Based on these verifications, we are preparing a consensus statement on the appropriate use of IN based on the fact-finding survey, while developing indigo containing capsule that disintegrates in the large intestine for the clinical trial (first in human) in order to reduce side effects because indigo is extracted as the active ingredient of IN and is assumed to be pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2022.00018 Intest Res 2023;21(2):174-176","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/23/ir-2022-00018.PMC10169512.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performing colonoscopy before steroid induction is associated with shorter steroid use in patients with ulcerative colitis.","authors":"Taku Kobayashi,&nbsp;Eri Udagawa,&nbsp;Lisa Hirose,&nbsp;Toshifumi Hibi","doi":"10.5217/ir.2021.00164","DOIUrl":"https://doi.org/10.5217/ir.2021.00164","url":null,"abstract":"<p><strong>Background/aims: </strong>Risks of long-term steroid use in patients with ulcerative colitis (UC) outweigh the benefits, thus dosing should be tapered once a response is achieved. Colonoscopy is a key technique for assessing disease severity and optimizing treatment involving steroids. This retrospective longitudinal cohort study of patients with UC explored factors associated with the duration of systemic steroid use.</p><p><strong>Methods: </strong>The Japan Medical Data Center database, an employer-based insurance claims database, was used to select individuals initiating prednisolone, with a prescription issued between January 1, 2010, and January 31, 2018. The study included adults with a confirmed diagnosis of UC, who had received ≥1 year of continuous treatment with 5-aminosalicylic acid, biologics, or thiopurine. Factors associated with prednisolone duration were assessed using a multivariate regression model.</p><p><strong>Results: </strong>Median duration of prednisolone treatment was 98 days, and colonoscopy was performed ≤1 month before or at the first prescription of prednisolone (index date) in 32.8% of patients (607/1,853). Shorter durations of prednisolone treatment were associated with colonoscopy ≤1 month before or at the index date and higher prednisolone dose at index date, with incidence rate ratios (IRRs) of 0.776 (95% confidence interval [CI], 0.682-0.884; P<0.001) and 0.998 (95% CI, 0.996-1.000; P=0.018), respectively. Charlson Comorbidity Index scores of 1 and ≥2 predicted longer prednisolone treatment (IRR, 1.332; 95% CI, 1.174-1.511; P<0.001 and IRR, 1.599; 95% CI, 1.357-1.885; P<0.001, respectively).</p><p><strong>Conclusions: </strong>Performing colonoscopy before or at the time of initiating steroid was associated with a shorter duration of steroid use in patients with UC.</p>","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/f6/ir-2021-00164.PMC10169511.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9450402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An oval-shaped calcification in Crohn's disease patient with mechanical ileus.","authors":"Young Min Kwak,&nbsp;Dong Hoon Baek,&nbsp;Byoung Chul Lee","doi":"10.5217/ir.2022.00134","DOIUrl":"https://doi.org/10.5217/ir.2022.00134","url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 270 view Board of Pusan National University Hospital. Written informed consent was obtained. Based on above information, what is the most likely diagnosis?","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/d6/ir-2022-00134.PMC10169524.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9454586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are the risks of colorectal cancer and biliary cancer really increased if patients with ulcerative colitis have primary sclerosing cholangitis?","authors":"Jung Wook Lee,&nbsp;Won Moon","doi":"10.5217/ir.2023.00049","DOIUrl":"https://doi.org/10.5217/ir.2023.00049","url":null,"abstract":"Article:","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/2d/ir-2023-00049.PMC10169523.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9443006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study.","authors":"Kyunghwan Oh,&nbsp;Hee Seung Hong,&nbsp;Nam Seok Ham,&nbsp;Jungbok Lee,&nbsp;Sang Hyoung Park,&nbsp;Suk-Kyun Yang,&nbsp;Hyuk Yoon,&nbsp;You Sun Kim,&nbsp;Chang Hwan Choi,&nbsp;Byong Duk Ye","doi":"10.5217/ir.2021.00173.e","DOIUrl":"https://doi.org/10.5217/ir.2021.00173.e","url":null,"abstract":"","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/12/ir-2021-00173-e.PMC10169515.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9450172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}